Cambridge Heartwear Secures £184 Million NHS Tender for HeartSense Wearable

CAMBRIDGE, England, Oct. 6, 2026 /CourierPR/ -- Cambridge Heartwear plc has secured a landmark £184 million tender with the National Health Service (NHS) of the UK for its HeartSense wearable technology. This agreement marks a significant advancement in global medical technology and cardiovascular diagnostics, enabling the deployment of advanced cardiac monitoring technology across primary and secondary care and civil service departments.

HeartSense is the world's first medical-grade, multi-channel, portable, wirelessly charged ECG wearable, designed to be straight to one's mobile phone. The device combines diagnostic-grade multi-channel ECG monitoring, adaptive artificial intelligence, and wireless charging in a single, ergonomic design. Manufactured in Britain, HeartSense is engineered to help identify cardiovascular disease and stroke risk before conditions become acute, giving healthcare professionals and patients access to continuous, real-time ECG data on a mobile phone.

The partnership with the NHS Supply Chain allows Integrated Care Boards to deploy HeartSense at scale, supporting the delivery of diagnostic-quality heart monitoring beyond hospital environments. The initiative is intended to reduce pressure on secondary care services while improving access to high-quality cardiac diagnostics in community settings.

HeartSense is UKCA approved and ISO 13845 certified, with FDA 510(k) applications currently in progress. The device is also supported by 86 patents, highlighting the company's commitment to innovation and technological advancement. The agreement with the NHS is expected to significantly enhance the capabilities of the UK's healthcare system, providing patients with a more preventative approach to heart disease and enabling more informed clinical decision-making.

Cambridge Heartwear, based at Cambridge Science Park, is a medical technology company dedicated to making heart health monitoring simple, accessible, and accurate. The company's proprietary engineering and AI technology are designed to empower patients and healthcare professionals with diagnostic-quality cardiovascular insights anytime, anywhere. HeartSense helps detect heart conditions earlier, enabling more informed clinical decision-making and better patient care.

The £184 million tender is a testament to the company's commitment to advancing medical technology and improving patient outcomes. With HeartSense, Cambridge Heartwear is poised to revolutionize the way heart disease is monitored and managed, providing a more comprehensive and accessible solution for patients and healthcare providers alike.